Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy
This study evaluated the outcomes of
PTC patients with indeterminate response after initial therapy. It was further
determined whether the indeterminate findings predicted outcomes more precisely.
Patients were further classified into 3 groups based on risk of structural
persistence/recurrence: Tg group: detectable thyroglobulin,
negative antithyroglobulin antibody, regardless nonspecific imaging findings;
TgAb group: positive antithyroglobulin antibody, regardless
thyroglobulin levels and nonspecific imaging findings, and Image group:
nonspecific findings on neck ultrasonography or faint uptake in the thyroid bed
on whole-body scan, undetectable thyroglobulin and negative antithyroglobulin
antibody. Sixty-six patients aged 44.1±12.7 years were studied, of whom
58 (87.9%) were females. All patients underwent total thyroidectomy, and
52 patients (78.8%) received radioiodine. After 5.7 years
(P25–75 2.6–9.75 years) of follow-up, most patients
(89.4%) were reclassified as having an excellent response or remained in
the indeterminate response to therapy. Structural recurrence/persistence
disease was detected in 7 (10.6%) patients. The
persistence/recurrence rate in groups were as follow: Tg,
2.63%; TgAb, 31.25%; Image, 8.3%
(p=0.007). The 10-years disease-free survival rate in the TgAb ...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Landenberger, Giullia Menuci Chianca de Souza Salerno, Marianna Lins Golbert, Lenara de Souza Meyer, Erika Laurini Tags: Endocrine Care Source Type: research
More News: Cancer & Oncology | Carcinoma | Endocrinology | Hormones | Men | PET Scan | Study | Thyroid | Thyroid Cancer | Thyroidectomy